---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-025440"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2026-06-16T20:11:35+00:00"
generated_at: "2026-06-16T20:12:16.549547+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics details five IRD gene therapy programs; four data readouts expected in 2027, cash runway to 2029

## Summary
- OPGx-RDH12 enters clinical testing in Q4 2026; OPGx-MERTK Q1 2027; OPGx-RHO H2 2027.
- OPGx-LCA5 Phase 3 dosing expected Q4 2026; OPGx-BEST1 topline data from Cohort 1 due September 2026.
- Four clinical data readouts from across the pipeline expected in 2027.
- Cash runway into 2029 expected to fund multiple clinical inflection points and potential product approvals.
- Global IRD prevalence estimates provided: RDH12 ~30,900, MERTK ~21,960, RHO ~30,200, LCA5 ~3,240, BEST1 ~21,800 patients.

## SEC filing metadata
- accession: 0001140361-26-025440
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2026-06-16T20:11:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036126025440/0001140361-26-025440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036126025440/ef20076319_form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-025440
- JSON: https://secwatch.observer/filing/0001140361-26-025440.json
- Plain text: https://secwatch.observer/filing/0001140361-26-025440.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.